An observational study in Prostate Cancer (Diagnosis), Quality of Life and Reliability, sponsored by Lokman Hekim University. Completed at 1 site in Turkey (Türkiye). Open to male participants. Per ClinicalTrials.gov, last updated 2026-03-05.
Sponsored by Lokman Hekim University · Observational
This study will evaluate the cross-cultural adaptation, validity, and reliability of the Turkish version of the UCLA Prostate Cancer Index in men diagnosed with prostate cancer. The original instrument will be translated and culturally adapted following standardized procedures. The psychometric properties of the Turkish version will be examined in patients attending routine follow-up visits at a urology clinic.
Internal consistency will be assessed using Cronbach's alpha coefficients, and test-retest reliability will be evaluated using intraclass correlation coefficients (ICC) in a subset of participants. Measurement error will be determined by calculating the standard error of measurement (SEM) and the smallest real difference at the 95% confidence level (SRD95). Construct validity will be examined through exploratory factor analysis, and convergent validity will be assessed by testing predefined hypotheses regarding correlations between the UCLA Prostate Cancer Index and established quality-of-life instruments (SF-36 and EORTC QLQ-PR25).
The findings are expected to provide a reliable and valid prostate cancer-specific quality-of-life assessment tool for use in Turkish-speaking populations.
6,370 studies on the registry are indexed under Prostatic Neoplasms; 1,400 are open to participants now.
This study's enrollment of 115 is below the median of 200 across 1,181 observational studies indexed under Prostatic Neoplasms.
Browse Prostatic Neoplasms studies →Lokman Hekim University is the lead sponsor of 41 studies on the registry; 16 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The study population consists of men aged 45 years and older who have been diagnosed with prostate cancer and are attending routine follow-up visits at a urology outpatient clinic in Türkiye.
Exclusion Criteria:
This cohort will consist of men aged 45 years and older who have been diagnosed with prostate cancer and are attending routine follow-up visits at a urology outpatient clinic
Other: Questionnaires
Participants will complete the Turkish version of the UCLA Prostate Cancer Index along with the SF-36 and EORTC QLQ-PR25 questionnaires. No intervention will be applied.
UCLA Prostate Cancer Index
The University of California, Los Angeles (UCLA) Prostate Cancer Index was developed in English in 1998 by Litwin et al. and has been psychometrically validated in prostate cancer populations. It evaluates urinary, sexual, and bowel function and the associated symptom-related bother in men treated for prostate cancer
Time frame: 1 hour
EORTC QLQ-PR25
The EORTC QLQ-PR25 is a prostate cancer-specific module consisting of 25 items and comprising six symptom subdomains: urinary symptoms, incontinence aid, bowel symptoms, hormonal treatment-related symptoms, sexual activity, and sexual functioning
Time frame: 1 hour
SF-36
It is a widely used 36-item questionnaire that evaluates health-related QoL across eight domains, including physical functioning, role limitations due to physical and emotional problems, mental health, vitality, social functioning, bodily pain, and general health
Time frame: 1 hour
Plan to share: Undecided
No publications or documents are linked to this record.
This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Lokman Hekim University